NASDAQ:AXDX - Accelerate Diagnostics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Accelerate Diagnostics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $16.51 -0.08 (-0.48 %) (As of 02/16/2020 04:00 PM ET) Add Compare Today's Range$16.36Now: $16.51▼$16.7150-Day Range$16.35MA: $17.11▼$18.7552-Week Range$14.27Now: $16.51▼$24.00Volume142,042 shsAverage Volume154,187 shsMarket Capitalization$902.27 millionP/E RatioN/ADividend YieldN/ABeta2.84 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:AXDX Previous Symbol CUSIPN/A CIK727207 WebN/A PhoneN/ADebt Debt-to-Equity Ratio12.81 Current Ratio21.93 Quick Ratio20.65Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.67 million Price / Sales159.13 Cash FlowN/A Price / Cash FlowN/A Book Value$1.06 per share Price / Book15.58Profitability EPS (Most Recent Fiscal Year)($1.62) Net Income$-88,330,000.00 Net Margins-1,116.69% Return on Equity-249.46% Return on Assets-51.36%Miscellaneous Employees287 Outstanding Shares54,650,000Market Cap$902.27 million Next Earnings Date2/18/2020 (Estimated) OptionableOptionable Receive AXDX News and Ratings via Email Sign-up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AXDX Rates by TradingView Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions What is Accelerate Diagnostics' stock symbol? Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX." How were Accelerate Diagnostics' earnings last quarter? Accelerate Diagnostics Inc (NASDAQ:AXDX) posted its earnings results on Thursday, November, 7th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.38) by $0.01. The medical research company earned $2.27 million during the quarter, compared to analyst estimates of $3.15 million. Accelerate Diagnostics had a negative return on equity of 249.46% and a negative net margin of 1,116.69%. View Accelerate Diagnostics' Earnings History. When is Accelerate Diagnostics' next earnings date? Accelerate Diagnostics is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Accelerate Diagnostics. What guidance has Accelerate Diagnostics issued on next quarter's earnings? Accelerate Diagnostics updated its FY 2020 After-Hours earnings guidance on Wednesday, January, 15th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $16-18 million, compared to the consensus revenue estimate of $27.93 million. What price target have analysts set for AXDX? 4 equities research analysts have issued 12-month target prices for Accelerate Diagnostics' shares. Their forecasts range from $16.00 to $20.00. On average, they expect Accelerate Diagnostics' share price to reach $18.33 in the next twelve months. This suggests a possible upside of 11.0% from the stock's current price. View Analyst Price Targets for Accelerate Diagnostics. What is the consensus analysts' recommendation for Accelerate Diagnostics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accelerate Diagnostics. What are Wall Street analysts saying about Accelerate Diagnostics stock? Here are some recent quotes from research analysts about Accelerate Diagnostics stock: 1. According to Zacks Investment Research, "Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, a rapid diagnostic platform for diagnosis in life-threatening bacterial infections and OptiChem(R) surface coatings for use in micro arraying components. Accelerate Diagnostics Inc., formerly known as Accelr8 Technology Corp., is based in Denver, Colorado. " (1/16/2020) 2. BTIG Research analysts commented, "Neutral AXDX reported Q1 revenue of $1.75M, short of consensus’ $1.9M forecast. Revenue was down sequentially by 4%. Although we had expected a revenue stepdown given the typical cadence of placements-to- conversions, the magnitude of the decline was less than we expected. In Q1, the company added 75 commercially contracted placements vs. 133 in 4Q18; to clarify, commercial placements refer to customers that have agreed to install and run tests (may or may not be active users). The company still sees a 4-9 month lag before instruments become active. On expectations for 2019, mgmt continues to target 300-400 placements as a full transition to the rental model and more comprehensive body of positive studies may drive up volumes." (5/12/2019) Has Accelerate Diagnostics been receiving favorable news coverage? Media stories about AXDX stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Accelerate Diagnostics earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Accelerate Diagnostics. What other stocks do shareholders of Accelerate Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), BIOLASE (BIOL), Alibaba Group (BABA), ABIOMED (ABMD), Gilead Sciences (GILD), AT&T (T) and Vuzix (VUZI). Who are Accelerate Diagnostics' key executives? Accelerate Diagnostics' management team includes the folowing people: Mr. Lawrence Mehren, Pres, CEO, Director and Interim Head of Europe, Middle East & Africa (Age 53)Mr. Steve Reichling, Chief Financial Officer (Age 41)Mr. Ron Price, Sr. VP & Head of Commercial Operations - Americas (Age 55)Mr. Kurt Reinhardt, Head of OperationsDr. Romney M. Humphries, Chief Scientific Officer (Age 38) Who are Accelerate Diagnostics' major shareholders? Accelerate Diagnostics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Credit Suisse AG (5.68%), Chicago Capital LLC (2.40%), ArrowMark Colorado Holdings LLC (2.04%), Cannell Peter B & Co. Inc. (2.00%), Griffin Asset Management Inc. (1.82%) and State Street Corp (1.10%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, John Patience, Steven Reichling and Thomas D Brown. View Institutional Ownership Trends for Accelerate Diagnostics. Which major investors are selling Accelerate Diagnostics stock? AXDX stock was sold by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Credit Suisse AG, Stifel Financial Corp, Barclays PLC, Cannell Peter B & Co. Inc., Bank of America Corp DE, New York State Common Retirement Fund and SeaCrest Wealth Management LLC. View Insider Buying and Selling for Accelerate Diagnostics. Which major investors are buying Accelerate Diagnostics stock? AXDX stock was purchased by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Griffin Asset Management Inc., UBS Group AG, ArrowMark Colorado Holdings LLC, California Public Employees Retirement System, State Street Corp, M&T Bank Corp and Bank of New York Mellon Corp. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, John Patience, Steven Reichling and Thomas D Brown. View Insider Buying and Selling for Accelerate Diagnostics. How do I buy shares of Accelerate Diagnostics? Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Accelerate Diagnostics' stock price today? One share of AXDX stock can currently be purchased for approximately $16.51. How big of a company is Accelerate Diagnostics? Accelerate Diagnostics has a market capitalization of $902.27 million and generates $5.67 million in revenue each year. The medical research company earns $-88,330,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Accelerate Diagnostics employs 287 workers across the globe.View Additional Information About Accelerate Diagnostics. MarketBeat Community Rating for Accelerate Diagnostics (NASDAQ AXDX)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 311 (Vote Outperform)Underperform Votes: 288 (Vote Underperform)Total Votes: 599MarketBeat's community ratings are surveys of what our community members think about Accelerate Diagnostics and other stocks. Vote "Outperform" if you believe AXDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXDX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/16/2020 by MarketBeat.com StaffFeatured Article: How prevalent are 12b-1 fees?
